U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
PATERI MAD HODDING SOLUTION
FORM PTO-1449

Sheet _ 1 _ of _ 1 _

LIST OF ART CITED BY APPLICANT

SERIAL NO.: 09/550,371 ATTY. DOCKET: 17328. TITLE: METHOD FOR TREATING PAIN BY APPLICANT: AOKI, ET AL., PERIPHERAL ADMINISTRATION OF A **NEUROTOXIN** FILING DATE: April 14, 2000 GROUP: 1653

UNITED STATES PATENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CHK	AA	6,113,915	9/5/00	AOKI	424	236	•
		,					

FOREIGN PATENT DOCUMENTS

		2002-11-11				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (yes/a)
 						

OTHER ART

	(Including Author, Tide, Date, 1 crument 1 ages, etc.)						
	T						
<u> </u>	 						
	-						
	-						
·							
L							

DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Serial No. U.S. Department of Commerce, Patent and Trademark Office Atty Docket No. PTO form 1449 19/630,26 09/550,371 17328 (AP) INFORMATION DISCLOSURE STATEMENT BY APPLICANT Applicant(s) Aoki et al. (Use several sheets if necessary) Group /653 Filing Date October 4, 2000 U.S. Patent Documents Filing Date Document *Examiner Subclass If Appropriate Class Name Date Number Initial 5/26/00 First 6,063,768 CHK AA · AB AC AD. AE. AF AG AH AJ ΑK Foreign Patent Documents **Translation** Yes Subclass Class Country Date Document AL AM AN AO AP ART (Including Author, Title, Date, Pertinent Pages, Etc.) OTHER AQ. AR AS 105 Date Considered Examiner *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

> SUPPLEMENTAL LIST OF ART CITED BY APPLICANT

DIST OF	AKI CIIDD DI MILESCOLLE
ATTY. DOCKET: 17328 (BOT).	SERIAL NO.: 09/550,371 10/630, 206
APPLICANT: AOKI, et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATIONOF A NEUROTOXIN
FILING DATE: APRIL 14, 2000	GROUP: 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMK	AA	6,113,915	9/5/00	AOKI	_424		
	AB						
	AC						
	AD						
	AE			<u> </u>		L	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
CMY	BA	WO 97/34624	9/25/97	PCT			
-4	BB	WO 96/33273	10/24/96	PCT			· · ·
CM	BC	WO 95/30431	11/16/95	PCT	L		

•		(Including Author, Title, Date, Pertinent Pages, etc.)
CMK	CA	Guyer, B., Mechanism of borulinum toxin in the relief of chronic pain, Current Review of Pain, 1999, 3:427-431, XP-001031379
1	СВ	Carruthers, A., et al., Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections,
	CC	Diaz, J., et al., Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin, Anesthesi logy, V 91, No. 3, Sep 1999, pp. 877-879, XP-001031347
	CD	Silberstein, S., et al., Botulinum toxin type A as a migraine preventive treatment, Headache 2000:40:445-450, XP-002182692
CMK	CE	Gobel, H., et al., Evidence-based medicine: botulinum toxin A in migraine and tension-type headache, Journal of Neurology, 2001 248 Supp 1: I/34-I/38, XP-002182693
4	,	

EXAMINER	(h)		DATE CONSIDERED	729/		
*EXAMINER:	Initial if reference considered, v	hether or not citation	n is in conformance with MPEP	609; Draw lin	e through citation	ifntin
	d not considered. Include conv.				•	

U.S. DEPARTMENT OF COMMERC	
PATENT AND TRADEMARK OFFICE	Έ
FORM PTO-1449	

Sheet	1	of	1
-------	---	----	---

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 09/550,371 10/630, 206
APPLICANT:	Aoki et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	04/14/2000	GROUP: _1646 /65}

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CME	AA	6,063,768	5/16/00	FIRST			
	AB		*				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
BA						
BB						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CMK	CA	Cheng, Guang-Shing; Botox, Dermabrasion Treated Facial Leiomyomas; Skin & Allergy News 2000;31(3):16.
1	СВ	First, E. et al.; Painful Cervical Dystonia: Response to Treatment with Botulinum Toxin; Mov Disord 1998;13(Suppl2):100.
	CC	Guyer, Barry M.; Mechanism of Botulinum Toxin in the Relief of Chronic Pain; Curr Rev Pain 1999;3(6):427-431.
	CD	Li, Yan, et al.; A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen after Reconstitution with Native Heavy Chain; Biochemistry 1994, 33, 7014-7020.
	CE	Schantz, Edward J., et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; Microbiological Reviews Mar. 1992, pp. 80-99, Vol. 56, No. 1.
	CF	Tarsy, Daniel, et al.; Painful Cervical Dystonia: Clinical Features and Response to Treatment With Botulinum Toxin; Mov Disord 1999;14(6):1043-1045.
Cik	CG	Zhou, Liqing, et al.; Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain; Biochemistry 1995, 34, 15175-15181.
	СН	

EXAMINER	Chi	DATE CONSIDERED _	1-403
	if reference considered, whether or not citation	on is in conformance with MPEP 609;	Draw line through citation if not i
conformance and not o	ancidered. Include cany of this form with nev	t communication to applicant	

Sheet	1	of	4

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/630, 266
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMK	AA	5,714,468	2/3/98	BINDER			
7	AB	5,766,605	6/16/98	SANDERS ET AL.			
Chik	AC	5,989,545	11/23/99	FOSTER ET AL.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
CMK	BA	94/15629	7/21/94	PCT			
	BB	96/33273	10/24/96	PCT	T		
7	BC	98/07864	2/26/98	PCT		,	
Crt	BD	99/17806	4/15/99	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

C	ΛK	CA	Barwood, Shane, et al.; Analgesic Effects of Botulinum Toxin A: A Randomized, Placebo- Controlled Clinical Trial; Developmental Medicine & Child Neurology, 2000; 42:116-121
	\mathcal{T}	СВ	Bigalke, H., et al.; Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture; Brain Research, 360 (1985); 318-324.
	 -	СС	Bigalke, H., et al.; Tetanus Toxin and Botulinum A. Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord; Naunyn-Schmiedeberg's Arch. Pharmacol (1981); 316:244-251.
			Cheshire, et al.; Botulinum Toxin in the Treatment of Myofascial Pain Syndrome; Pain, 1994; 59(1):65-9.
CA	10	CE	DiStefano, P. S., et al.; Receptor Mediated Retrograde Axonal Transport of Neurotrophic Factors is Increased After Peripheral Nerve Injury; Progress in Brain Research (1994); Vol. 103; Chapter 4; 35-42.

EXAMINER *EXAMINER: Initial if reference considered, whether or not citation is conformance and not considered. Include copy of this form with next conformance and not considered.	DATE CONSIDERED s in conformance with MPEP 609; D mmunication to applicant.	429/05 Traw line through citation if not in
conformance and not considered. Include copy of this form with next con	mmunication to applicant.	

U.S. DEPARTMEI	NT OF COMMERCE
PATENT AND TR	ADEMARK OFFICE
FORM PTO-1449	

Sheet	2	of	4

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/630, 206
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: 1653

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

		CF	Dixon, W. J.; Efficient Analysis of Experimental Observations; Ann. Rev. Pharmacol.
9	7K		<u>Toxicol.</u> (1980); 20:441-462.
		CG	12 do aloson, 2., or al., The I of hattin I est. A Quantitative study of the Analyesic Effects of
			Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats; Pain (1977); 4:161-
			174.
		CH	1 2 20, 0., of al., of ash actural Localization of Start -25 within the Rai Spinal Cora and
			Peripheral Nervous System; The Journal of Comparative Neurology (1995); 356:152-163.
1 1		CI	Fauci, A.S., et al. (Editors); Harrison's Principles of Internal Medicine, 14th Edition (1998):
			McGraw-Hill; 2064-2065.
		ದ	Garner, C.G., et al.; Time Course of Distant Effects of Local Injections of Botulinum Toxin;
<u> </u>			Movement Disorders; Vol. 8, No. 1; 1993.
		CK	1
	ł		(H)noradrenaline and (H)GABA from Rat Brain Homogenate; Experientia 44 (1988): 224-
			226.
		CL	Habermann, E.; I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding
to Synaptosomes and Ascent to the Spinal Cord; Naunyn Schmiedeberg's		to Synaptosomes and Ascent to the Spinal Cord; Naunyn Schmiedeberg's Arch. Pharmacol.;	
			281, 47-56 (1974).
	- 1	CM	Habermann, E., et al.; Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit
- 1			Noradrenaline Release from Cultured Mouse Brain; Journal of Neurochemistry; Vol. 51; No.
			2 (1988); 522-527.
- 1		CN	Hagenah, R., et al.; Effects of Type A Botulinum Toxin on the Cholinergic Transmission at
- 1		1	Spinal Renshaw Cells and on the Inhibitory Action at Ia Inhibitory Interneurones: Naunyn-
			<u>Schmiedeberg's Arch. Pharmacol.</u> ; 299, 267-272 (1977).
1		co	Halpem, J.L., et al.; Neurospecific Binding, Internalization, and Retrograde Axonal
L			Transport; Date Unknown; pp. 221-241.
T^{-}			Johnson, E., et al.; Biomedical Aspects of Botulinum Toxin; J. ToxicolToxin Reviews; Feb.
			18, 1999; 18(1):1-15.
CITE CQ Jung, H. H., et a		CQ	Jung, H. H., et al.; Expression of Neurotransmitter Genes in Rat Spinal Motoneurons After
			Chemodenervation with Botulinum Toxin; Neuroscience (1997); Vol. 78, No. 2; 469-479.
			1997), Vol. 78, No. 2; 409-479.

		4/201
EXAMINER CASE	DATE CONSIDERED	19/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/639 206
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: 1653

OTHER ART (Continued)

(Including Author, Title, Date, Pertinent Pages, etc.)

		CD	Kim, S. H., et al.; An Experimental Model for Peripheral Neuropathy Produced by Segmental
	MK	CK	Spinal Nerve Ligation in the Rat, Pain, 50 (1992); 355-363.
	Ť	CS	Li et al.; Biochemistry; 33:7014-7020 (1994).
		СТ	Mochida, S., et al.; Impairment of Syntaxin by Botulinum Neurotoxin C ₁ or Antibodies Inhibits Acetylcholine Release but not Ca ²⁺ Channel Activity; Neuroscience (1995); Vol. 65; No. 3; 905-915.
		CU	Naumann, et al.; Botulinum Toxin Type A in the Treatment of Focal, Axillary and Palmar Hyperhidrosis and Other Hyperhidrotic Conditions; European Journal of Neurology, 1999; Vol. 6(suppl4):S3-S10 and S111-S115.
		CV	Nelson, P.G., et al.; Mouse Spinal Cord in Cell Culture. IV. Modulation of Inhibitory Synaptic Function; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1178-1187.
		CW	Osen-Sand, A., et al.; Inhibition of Axonal Growth by SNAP-25 Antisense Oligonucleotides in vitro and in vivo; Nature; 29 July 1993; Vol. 364; 445-448.
		CX	Pearce, L. B., et al.; Pharmacologic Characterization of Botulinum Toxin for Basic Science and Medicine; Toxicon (1997); Vol. 35, No. 9; 1373-1412.
		CY	Ragona, et al.; Management of Parotid Sialocele with Botulinum Toxin; Laryngoscope, 109:August 1999; p. 1344-36
		CZ	Ransom, B.R., et al.; Mouse Spinal Cord in Cell Culture. I. Morphology and Intrinsic Neuronal Electrophysiologic Properties; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1132-1150.
		DA	Ransom, B.R., et al.; Mouse Spinal Cord in Cell Culture. II. Synaptic Activity and Circuit Behavior; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1151-1162.
		DB	Ransom, B.R., et al.; Mouse Spinal Cord in Cell Culture. III. Neuronal Chemosensitivity and its Relationship to Synaptic Activity; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1163-1177.
		DC	Rees, H., et al.; Do Dorsal Root Reflexes Augment Peripheral Inflammation?; Neuro Report; Vol. 5, No. 7; 21 March 1994; 821-824.
Cr	16	DD	Sanchez-Prieto, J., et al.; Botulinum Toxin A Blocks Glutamate Exocytosis from Guinea-Pig Cerebral Cortical Synaptosomes; Eur. J. Biochem. (1987); 165:675-681.

EXAMINER OF L	DATE CONSIDE	RED 4/29/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 4 of	f 4
------------	-----

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 19/630, 206
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: /653

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

		DE	Shantz, E.J., et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins
1 /	CMK	DE	
L`			in Medicine; Microbiol Rev.; 56:80-99 (1999).
		DF	Simpson, L.; Botulinum Toxin: Potent Poison, Potent Medicine; Hospital Practice; April 15,
l			1999; 34(4):87-91.
		DG	Singh, B.R.; Critical Aspects of Bacterial Protein Toxins; Natural Toxins II (1996); Plenum
l	l l		Press, New York; pp. 63-84.
		DH	Tonra, J. R., et al.; Axotomy Upregulates the Anterograde Transport and Expression of
ļ	1 '		Brain-Derived Neurotrophic Factor by Sensory Neurons; The Journal of Neuroscience; June
		i	1, 1998; 18(11):4374-4383.
		DI	Tsuda, M., et al.; In vivo Pathway of Thermal Hyperalgesia by Intrathecal Administration of
]	1 .		α, β-methylene ATP in Mouse Spinal Cord: Involvement of the Glutamate-NMDA Receptor
Ì	j		System; Br. J. Pharmacol (1999); 127(2):449-456.
 		DJ	Wiegand, H., et al.; The Action of Botulinum A Neurotoxin on the Inhibition by Antidromic
	- []		Stimulation of the Lumbar Monosynaptic Reflex; Naunyn-Schmiedeberg's Arch. Pharmacol.
		(1977); 298:235-238.	
	+	DK	
İ			Intramuscular Injection; Nauyn-Schmiedeberg's Arch. Pharmacol.; 292, 161-165 (1976).
		DL	Williamson, L. C., et al.; Clostridial Neurotoxins and Substrate Proteolysis in Intact
		DL	Williamson, L. C., et al., Closiridial Neuroloxins and Substrate 1 roteolysis in triade
			Neurons; The Journal of Biological Chemistry; Mar. 29, 1996; Vol. 271:13; 7694-7699.
1		DM	Williamson, L. C., et al.; Differential Effects of Tetanus Toxin on Inhibitory and Excitatory
i			Neurotransmitter Release from Mammalian Spinal Cord Cells in Culture; Journal of
			Neurochemistry; 1992; Vol. 59:6; 2148-2157.
		DN	1, 222)
			pages 725-750.
		DO	Woolf, C. J., et al.; Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management;
			The Lancet; June 5, 1999; Vol. 353; 1959-1964.
		DP	Yaksh, T. L., et al.; Chronic Catheterization of the Spinal Subarachnoid Space; Physiology &
			Behavior (1976); Vol. 17:1031-1036.
	1V	DQ	Zhou et al., Biochemistry; 34:15175-15181 (1995).
Cr	/~		

				_
	α	<i>/</i>	•	4/201
EXAMINER	Chl	· -	DATE CONSIDERED	729/05
	if reference considered	l, whether or not	citation is in conformance with MPEP 609	; Draw line through citat

ion if not in conformance and not considered. Include copy of this form with next communication to applicant.